2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Melanoma
18
Neoplasm Metastasis
16
Carcinoma, Hepatocellular
15
Neoplasms
13
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Colorectal Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Small Cell Lung Carcinoma
5
Recurrence
5
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Liver Neoplasms
4
Glioblastoma
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Irinotecan
10
Fluorouracil
10
Leucovorin
9
Bevacizumab
9
Gemcitabine
8
Paclitaxel
7
Cisplatin
7
Capecitabine
7
Oxaliplatin
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Sorafenib
4
Drug Therapy
4
Cetuximab
4
pembrolizumab
3
apatinib
3
Radiotherapy
3
Ocoxin
3
Imatinib Mesylate
3
Folfox protocol
3
Everolimus
3
tislelizumab
2
spartalizumab
2
palbociclib
2
entinostat
2
encorafenib
2
camrelizumab
2
anlotinib
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled